Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function

Phosphoinositide 3-kinases (PI3Ks) are promising targets for therapeutic development in cancer. The class I PI3K isoform p110α has received considerable attention in oncology because the gene encoding p110α (PIK3CA) is frequently mutated in human cancer. However, little is known about the function o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2014-06, Vol.9 (6), p.e99486-e99486
Hauptverfasser:	Yea, Sung Su, So, Lomon, Mallya, Sharmila, Lee, Jongdae, Rajasekaran, Kamalakannan, Malarkannan, Subramaniam, Fruman, David A
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase AKT protein Analysis Animals Antibody-Dependent Cell Cytotoxicity - drug effects B cells Biochemistry Biology and life sciences Cancer Cancer therapies Cell Differentiation - drug effects Cell Survival - drug effects Chemokines Chemokines - biosynthesis Clinical trials Cytokines Cytotoxicity Cytotoxicity, Immunologic - drug effects Enzymes Female Health aspects Humans Immunology Immunosurveillance Immunotherapy Inhibitors Interferon Interferon-gamma - biosynthesis Isoenzymes - antagonists & inhibitors Isoenzymes - metabolism Isoforms Killer cells Killer Cells, Natural - cytology Killer Cells, Natural - drug effects Killer Cells, Natural - enzymology Kinases Laboratories Ligands Lymphocytes Lymphoma Medical research Medicine and Health Sciences Mice, Inbred C57BL Molecular biology Mutation Natural killer cells NK Cell Lectin-Like Receptor Subfamily K - metabolism NKG2 antigen Oral administration Phosphatidylinositol 3-Kinases - metabolism Phosphoinositide-3 Kinase Inhibitors Phosphorylation Phosphorylation - drug effects Phosphotransferases Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins c-akt - metabolism Research and Analysis Methods Signaling Toxicity Tumor cells Tumorigenesis Tumors γ-Interferon
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!